Neuroprotective Agents for Parkinson's Disease via D2/D3 Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmacotherapeutic agents for Parkinson's disease, particularly dopamine receptor agonists, face challenges in selectively targeting D2 and D3 receptors due to their shared agonist binding sites and widespread distribution, leading to inadequate treatment efficacy and oxidative stress-related side effects.
Innovation Solution
Development of novel compounds with specific formulas, such as those represented by IA and IB, which are designed to selectively bind to D2/D3 receptors, potentially reducing oxidative stress and improving neuroprotection by incorporating specific substituents and heteroatoms, thereby enhancing therapeutic efficacy and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dopamine receptor agonists are used to treat Parkinson's disease, then motor symptoms are improved, but oxidative stress and neurotoxicity increase
Solution Approach 1:
The patent modifies the chemical parameters of dopamine agonists by incorporating iron-chelating moieties and specific substituents (R1-R6 groups) to alter the pharmacological properties. This changes the interaction profile with dopamine receptors and iron ions, reducing oxidative stress while maintaining therapeutic efficacy
Solution Approach 2:
The invention creates composite pharmacological agents that combine dopamine agonist properties with iron-chelating capabilities in a single molecular structure. This dual-function compound addresses both the need for dopaminergic stimulation and the need to reduce iron-mediated oxidative damage
2Reliability
If L-dopa is used as gold-standard treatment, then dopaminergic function is restored, but side effects and neurotoxicity occur
Solution Approach 1:
The patent extracts and addresses the harmful oxidative component by incorporating iron-chelating functionality into the dopamine agonist structure. This allows the separation of therapeutic dopaminergic effects from harmful oxidative effects, eliminating neurotoxicity while preserving function restoration
Solution Approach 2:
The iron-chelating moiety acts as an intermediary that binds excess iron ions, preventing them from participating in harmful Fenton reactions. This intermediary function protects neurons from oxidative damage while the dopamine agonist portion maintains dopaminergic function
3Manufacturing precision
If D2 and D3 receptor agonists are developed, then receptor selectivity is challenging, but treatment precision can be improved
Solution Approach 1:
The patent applies local quality by introducing specific functional groups (R1-R6 substituents and iron-chelating moieties) at particular positions on the molecular scaffold. These localized modifications create differential binding affinities for D2 versus D3 receptors, achieving selectivity through specific local interactions rather than overall structural complexity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
A compound having formula I is useful for treating a neurodegenerative disease: I, R1 is an C1-12 organyl group; is a C1-12 heterocyclic ring system containing 5 to 12 ring atoms and up to three heteroatoms individually selected from the group consisting of N, O, S, and Se; R2 are C1-12 organyl groups; R7, R8 are each independently, hydrogen (H), hydroxyl, oxo (i.e., carbonyl), C1-8 alkyl, C1-8 alkoxyl, C2-8 alkenyl, C2-10 alkynyl, C5-7 cycloalkyl, C5-7 cycloalkenyl, halo, C1-4 aldehyde, or -NR4 q where R4 is H, C1-8 alkyl, C2-8 alkenyl, C4-8 cycloalkyl, C4-8 cycloalkenyl, or C6-10 aryl; o is 0, 1, 2, 3, or 4; A is a C6-12 aryl group, C5-12 heteroaryl group, or an optionally substituted 3-hydroxypyridin- 4(1H)-one; p is an integer from 1 to 6; and Zm is absent or a divalent linking moiety; and m is an integer representing the number of time Z is repeated.